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INTRODUCTION: Breast cancer metastases occurs in around 50% of all presentation. It is the second most
common type of cancer to metastasise to the GI tract but this only occurs in less than 1% of cases.
PRESENTATION OF CASE: We report a case that underwent treatment for invasive lobular cancer (ILC) of
the breast and 5 years later was found to have rectal and peritoneal metastasis. She is currently receiving
palliative management including chemotherapy in the form of weekly Paclitaxel (Taxol®) and stenting
to relieve obstruction.
CONCLUSION: There should be high clinical suspicion of bowelmetastasis in patients presentingwith pos-
itive faecal occult blood with or without bowel symptoms even if the incidence is less <1% of metastases,
particularly in cases where the initial breast tumour was large, with positive axillary nodes.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The risk of distant metastases from breast cancer is around 50%,
most commonly to nodes, lung, bones, brain and liver [1,2]. There
have been several reports of metastasis to GI tract although this is
rare and accounts for less than 1% of all metastatic cases.
In this paper we report the case of a patient who underwent
treatment for invasive lobular cancer (ILC) of the breast and 5 years
later was found to have rectal and peritoneal metastasis from the
breast primary.
2. Presentation of case
A 56 old lady was diagnosed with screen-detected right breast
cancer in 2010 for which she underwent a right mastectomy and
axillary node clearance. Her breast histology suggested 2 kinds of
cancer: one was a 102mm inﬁltrating lobular cancer which was
ER positive and HER2 negative; the second lesion was a grade 1
invasive ducal carcinoma measuring 8mm. Ki67 and progesterone
analysis are not routinely done as per NICE guidelines. 4 of 10
axillary nodes were positive for metastatic disease. She received
3 cycles of adjuvant chemotherapy in the form of Fluorouracil,
Epirubicin and Cyclophosphamide followed by 3 cycles of Taxotere
(FEC-T). Subsequently she received chest wall, axillary and supra-
clavicular fossa radiation of 15Gy ﬁve days of theweek for 3weeks.
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She underwent regular surveillance mammograms and CT scans
which suggested no evidence of local or distant recurrence.
In February 2015 she was recalled by the NHS Bowel Cancer
Screening Programme for a positive result on faecal occult blood
testing. The patient was otherwise asymptomatic at this stage. At
endoscopy, she was found to have a stricture in the rectum approx-
imately 16 cm from the anal verge. The stricture was negotiated
with a gastroscope but proximal bowel was loaded with hard fae-
ces and the procedure could not be continued. Biopsies were taken
fromthenarrowedarea conﬁrmingmetastatic lobular carcinomaof
breast. The specimen was CK7 and ER receptor positive and nega-
tive for HER2, CDX2 and CK20 as demonstrated in Figs. 1 and 2.
The conﬁrmation of metastatic lobular carcinoma was made on
the morphology on the H&E section and the ER and HER2 status
which was identical to the primary. She underwent a CT scan of
her chest, abdomen and pelvis. This identiﬁed the stricture in the
rectum at the recto-sigmoid junction. She was also found to have a
41×48×47mm left adnexal mass and several peritoneal deposits
were also noted. Her casewas discussed in the breast and colorectal
multidisciplinary meetings and all of these lesions and the adnexal
mass were thought to be breast metastases.
She was therefore referred to the oncologist for palliative
chemotherapy in the form of weekly Paclitaxel (Taxol®) for a total
of 18 cycles and will have a repeat CT after the 9th cycle to assess
response.
She has currently completed 3 cycles but started to develop
discomfort and a sense of incomplete evacuation. This has been
managedsymptomaticallyby the radiologist. Theyhave identiﬁed2
strictures, one known recto-sigmoid stricture and the second10 cm
proximal to it and deployed 2 interlocking stents 1st 8 cm and 2nd
6 cm long successfully to manage this as seen in Figs. 3, 4 and 5.
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Fig. 1. H&E section the lamina propria is expanded by small malignant cells.
Fig. 2. Immunohistochemistry show positive oestrogen receptor.
Fig. 3. Pre-procedure demonstrating 2 strictures.
3. Discussion
Breast cancer is the second most common cancer to metas-
tasise to the GI tract, second only to malignant melanoma [2,3].
Fig. 4. Successful dilation and deployment of stents.
Fig. 5. Post-procedure showing stent position and contrast through to rectum.
ILC accounts for 10–20% of breast tumours and is the most likely
breast cancer to metastasise due to its loss of cell–cell adhesion
molecules [4]. The risk of local or distant metastasis is 60% at the
time of ﬁrst presentation and 30–80% will develop distant metas-
tases after completing the treatment for cancer [5,6]. Although the
usual sites for any breast cancer metastases are liver, bone, lungs,
brain and nodes [1,2], secondary deposits to the GI tract have been
previously documented, but are certainly a rare entity. Borst and
Ingold, in their study of 2604 cases of breast cancer had reported GI
metastases inonly17 cases (0.7%) [7,8]. Anautopsy study suggested
that metastasis to the GI tract is more common than clinically sus-
pected and the true incidence is therefore not known [1,9]. Borst
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also reported that ILC was more likely to metastasise to the GI tract,
gynaecologic organs and peritoneum than invasive ductal carci-
noma [4,7,10]. The sites of metastases can be anywhere from the
oropharynx [4,11] to the anus [4,12,13]. The most common site is
stomach [14,15] followed by small bowel, with colorectal metas-
tasis being much rarer [2,4,5,16]. The most typical presentation is
the thickening and rigidity of the rectal wall, as seen in our case,
rather than identifying a localized mass [14].
Apart fromhistology of the cancer, the size of the primary breast
tumour and metastasis to regional nodes at time of diagnosis are
considered signiﬁcant risk factors for distant metastasis. Iorﬁda
et al. [17] suggested that a breast tumour greater than 2 cm in
diameter and node positive were both independent risk factors for
metastases and this was true in our patient who had a lesion over
10 cm in diameter with 4 metastatic nodes. The time from initial
diagnosis of breast cancer to metastasis can be just a few months
[18] to 5 years [19,20] to more than decades [1,2].
As ILCbehavesverydifferent fromotherknownbreast cancers in
terms of recurrence and sites of metastasis, it has been described
as a chronic disease by Anwar et al. [21]. Patients with this can-
cer should always be suspicious of a recurrence developing in a
local or distant site such as the GI tract, even years after curative
treatment is given. There should be a high index of suspicion for
bowel metastasis in a patient with known ILC if bowel symptoms
develop or if they are asymptomatic with a positive faecal occult
blood. Metastases to the GI tract is a late manifestation and pal-
liative chemotherapy is usually offered as ﬁrst line of treatment
to control tumour growth. Surgery has little role to play in this
situation unless the patient develops bowel obstruction or perfo-
ration [22]. About 53% [4,23]will have some response to treatment,
and the survival after treatment is poor but some cases of longer
survival are also reported [2,5].
4. Conclusion
Due to the relapsing and remitting nature of breast ILC, there
should be high clinical suspicion of bowel metastasis in patients
presenting with positive faecal occult blood with or without bowel
symptoms, particularly in cases where the initial breast tumour
was large,with positive axillary nodes.We recommend the suitable
mode of monitoring should be routine CTs in such cases. Another
consideration would be to enter these patients earlier into the
Bowel Cancer Screening Programme as breast cancers are second
most common cancer metastasizing to bowel. This case demon-
strates the value of long term follow-up of this patient cohort even
when they appear to be in remission.
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